GlybatomaqTM312317b: Novel Series of Quantum Thinking Ligands targeted to the Glioma target

GlybatomaqTM312317b: Ab initio Systematic Parameterization of Polarizable Force Field Quantum Chemistry mechanics-based free energy perturbation methodologies for calculating relative solvation free energies of a Novel Series of Quantum Thinking Ligands targeted to the ETS1, PTPRZ, CASP8AP2 and FAS, EPTP-ADAM22 Tudor domain of human PHF20-mediated Glioma and Glioblastoma cell apoptosis with Rb tumor suppressor agonistic properties; A Quantum Entropy and Special AI in practice.

Autorentext

Grigoriadis G. Ioannis has completed his PharmacistD at the age of 24 years from the Aristotle University of Thessaloniki School of Pharmacy. He has published more than 379 papers and He is the Chairman of the WAMS International Board for Pharmaceutical Biotechnology and Clinical Pharmacy and the scientific director of Biogenea Pharm.